Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued on Friday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of Oncternal Therapeutics in a research note on Friday, May 31st.

Oncternal Therapeutics Stock Down 1.2 %

ONCT opened at $7.60 on Friday. The firm has a market cap of $22.50 million, a P/E ratio of -0.62 and a beta of 1.38. Oncternal Therapeutics has a 52 week low of $5.57 and a 52 week high of $13.14. The business’s fifty day simple moving average is $8.54 and its 200 day simple moving average is $8.82.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($2.83) EPS for the quarter, beating analysts’ consensus estimates of ($2.88) by $0.05. The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.18 million. Oncternal Therapeutics had a negative return on equity of 107.67% and a negative net margin of 3,160.73%. During the same quarter last year, the company earned ($4.00) earnings per share. As a group, equities analysts expect that Oncternal Therapeutics will post -11.63 EPS for the current fiscal year.

Insiders Place Their Bets

In other Oncternal Therapeutics news, Director Robert James Wills purchased 3,086 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were purchased at an average cost of $8.96 per share, with a total value of $27,650.56. Following the purchase, the director now owns 10,000 shares in the company, valued at $89,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 11.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Quantum Private Wealth LLC bought a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 1st quarter, according to its most recent filing with the SEC. The firm bought 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned 0.94% of Oncternal Therapeutics as of its most recent filing with the SEC. Institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.